AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...
AbbVie is also developing oncology therapies beyond ADC. A key candidate in the company’s pipeline is etentamig/ABBV-383, a ...
OCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the ...
By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...
AstraZeneca PLC (NASDAQ:AZN) operates across global healthcare markets through advanced research pathways, biopharmaceutical ...
Here are 5 notable oncology FDA approvals from last month: ...
Equity-Insider.com News Commentary – The FDA approved the first perioperative immunotherapy for early gastric and gastroesophageal junction cancers last month, ushering ...
The FDA approved perioperative durvalumab with FLOT chemotherapy for eligible patients with resectable Stage II-IVA gastric and GEJ cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback